IntelGenx Technologies Corp. (T:IGX)

Business Focus: Generic Pharmaceuticals

Get the company report for the most recent outlook updated daily

Apr 08, 2024 07:45 am ET

IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Montelukast VersaFilm® has been administered to the first Parkinson’s Disease (“PD”) patients in the Phase 2 (‘MONTPARK’) clinical trial. MONTPARK (EudraCT...

Apr 05, 2024 07:45 am ET

IntelGenx Updates Status of Buprenorphine Buccal Film ANDA

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC (“Xiromed”), has received a Complete Response Letter (“CRL”) from the U.S....

Mar 21, 2024 07:30 am ET

IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results

IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and twelve-month periods ended December 31, 2023. All dollar amounts are expressed in U.S. currency, unless otherwise...

Mar 14, 2024 04:30 pm ET

IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its fourth quarter and full year 2023 financial results before market open on Thursday, March 21, 2024. An...

Mar 11, 2024 07:45 am ET

IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company”) announces that its wholly-owned subsidiary, IntelGenx Corp. (“IntelGenx Corp.”), has entered into a third amended and restated loan agreement dated as of March 8, 2024 (amending...

Feb 20, 2024 10:50 am ET

UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced the launch of a Regulation A offering of up to 2,000,000 shares of Series A Convertible Cumulative Preferred Stock (“Series A Preferred Stock”), par value...

Feb 20, 2024 07:50 am ET

IntelGenx Launches Preferred Share Regulation A Offering

Feb 05, 2024 08:00 am ET

Studies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® Platform

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced positive results from a proof-of-concept (“POC”) study to assess the palatability, owner-perceived acceptability, and ease of repeated administration of...

Dec 18, 2023 07:15 am ET

IntelGenx Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm®

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has entered into development and license agreements (collectively the “Agreements”) with a wholly-owned subsidiary of Covenant Animal Health Partners, LLC...

Dec 05, 2023 08:00 am ET

IntelGenx Announces Closing of Previously Announced Subsequent Non-Brokered Private Placement With atai Life Sciences for Aggregate Gross Proceeds of US$750,000

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”) announces the closing of the previously announced subsequent non-brokered private placement (the “Subsequent atai Subscription”) of 750 units (“US Units”) with atai...

Dec 04, 2023 08:00 am ET

IntelGenx Announces Changes to its Board of Directors

IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) announces the resignation of Frank Stegert and Srinivas Rao from the Board of Directors of the Company (the “Board”) effective December 2, 2023....

Nov 28, 2023 04:05 pm ET

IntelGenx Announces Shareholder Approval of Financing Transactions

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”) is pleased to announce that, at its meeting held earlier today (the “Special Meeting”), the shareholders (the “Shareholders”) voted to approve all proposals related...

Nov 14, 2023 07:30 am ET

IntelGenx Receives Approval to Conduct ’MONTPARK’ Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Parkinson's Disease

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that the Swedish Medical Products Agency (“MPA”), the Swedish Ethical Review Authority, and the Regional Biobank Centre have approved the planned clinical study...

Nov 13, 2023 08:00 am ET

IntelGenx Reminds Shareholders to Vote at Upcoming Special Meeting

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”) wishes to remind its shareholders of record as of October 2, 2023 (the “Shareholders”) of the importance of a vote FOR the various proposals detailed below at the...

Nov 09, 2023 04:05 pm ET

IntelGenx Reports Third Quarter 2023 Financial Results

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the third quarter ended September 30, 2023. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and...

Nov 06, 2023 08:30 am ET

IntelGenx Announces Co-development and Commercialization of Cannabinoid-Infused VersaFilm® Products with Tilray

IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it and Tilray Brands Inc. (“Tilray”) have entered into a further amendment (the “Second Amendment”) to their November 2018 license, development and supply...

Nov 02, 2023 04:45 pm ET

IntelGenx to Report Third Quarter 2023 Financial Results on November 9, 2023 – Conference Call to Follow

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its third quarter 2023 financial results after market close on Thursday, November 9, 2023. An accompanying...

Sep 21, 2023 08:00 am ET

IntelGenx Provides RIZAFILM® U.S. Commercialization Update

IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has received the first purchase order (“PO”) for RIZAFILM®1 from its commercial partner in the United States, Gensco Pharma (“Gensco®”). The PO triggers...

Sep 19, 2023 08:00 am ET

IntelGenx Provides Regulatory Update for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film

IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today provided a regulatory update on Buprenorphine Buccal Film, for which an abbreviated new drug application (“ANDA”) has been filed with the U.S. Food and Drug Administration...

Aug 31, 2023 08:30 am ET

IntelGenx Announces Closing of First Tranche of Non-Brokered Private Placement From Strategic Partner for Approximate Aggregate Gross Proceeds of US$3 Million (Including US$750,000 to be Received by t

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”) announces the closing of the first tranche of a non-brokered private placement (the “Offering”) of units (“Units”) from atai Life Sciences AG (“atai”) for aggregate...

Aug 14, 2023 04:03 pm ET

IntelGenx Reports Second Quarter 2023 Financial Results

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the second quarter ended June 30, 2023. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and...

Aug 10, 2023 04:30 pm ET

IntelGenx Announces First Agreement for CDMO Packaging Services

IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has entered into a binding term sheet agreement for the packaging of a pharmaceutical oral film product that its undisclosed CDMO customer is planning to...

Aug 07, 2023 04:30 pm ET

IntelGenx to Report Second Quarter 2023 Financial Results on August 14, 2023 – Conference Call to Follow

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its second quarter 2023 financial results after market close on Monday, August 14, 2023. An accompanying...

Aug 01, 2023 08:00 am ET

IntelGenx Completes Enrollment for ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has completed patient enrollment in the ongoing Montelukast VersaFilm® Phase 2a (“BUENA”) clinical trial in patients with mild to moderate Alzheimer’s...

Jul 25, 2023 08:00 am ET

IntelGenx Provides Update on Research Collaboration Evaluating Montelukast VersaFilm® for the Treatment of Parkinson’s Disease

IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced the execution of a Research Grant Agreement with Karolinska University Hospital and that the manufacturing of both active and placebo films are underway in...

Jul 21, 2023 04:30 pm ET

IntelGenx Announces a Change to its Board of Directors

IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) announces the resignation of Mr. J. Bernard (Bernie) Boudreau from the Board of Directors (the “Board”) of the Company effective today. Mr. Boudreau was a Director...

Jul 06, 2023 04:30 pm ET

IntelGenx Announces Voting Results on Election of Directors

IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) announces that, at the annual meeting of shareholders of the Company held on May 9, 2023 (the “Annual Meeting”), shareholders voted in favour of all items of...

May 31, 2023 08:00 am ET

IntelGenx Unveils Short-Term Commercial Objectives

IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it is executing on a plan focussed on near-term revenue generation. “There is no question in my mind that IntelGenx has great science, services, assets,...

May 17, 2023 08:00 am ET

IntelGenx Receives Amended DEL License to Conduct Third-Party Testing

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") a leading drug delivery company, is pleased to announce that it has received an amended Drug Establishment License (“DEL”) from Health Canada, allowing the Company to conduct...

May 11, 2023 04:05 pm ET

IntelGenx Reports First Quarter 2023 Financial Results

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the first quarter ended March 31, 2023. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and...

May 04, 2023 04:30 pm ET

IntelGenx to Report First Quarter 2023 Financial Results on May 11, 2023 – Conference Call to Follow

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its first quarter 2023 financial results after market close on Thursday, May 11, 2023. An accompanying...

Apr 27, 2023 04:30 pm ET

IntelGenx Extends Period to Exercise Certain Warrants

IntelGenx Technologies Corp. (TSX: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) announces that it has received conditional approval from the Toronto Stock Exchange to extend the expiry date of warrants originally issued to Cantone Research...

Apr 27, 2023 08:00 am ET

IntelGenx Announces Receipt of Complete Response Letter from the FDA for Xiromed-Partnered Buprenorphine Buccal Film

IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC (“Xiromed”), has received a Complete Response Letter (“CRL”) from the U.S....

Apr 17, 2023 08:15 am ET

IntelGenx Announces FDA Approval of RIZAFILM® for the Treatment of Acute Migraine

IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that the U.S. Food and Drug Administration (“FDA”) has approved the Company’s RIZAFILM® VersaFilm® 505(b)(2) new drug...

Apr 13, 2023 09:17 am ET

IntelGenx Announces Organizational Changes to Support Global Growth Strategy

IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced various changes to its management team. Following the planned retirement of its founder and CEO, Horst G. Zerbe, PhD, the new executive leadership...

Mar 29, 2023 04:05 pm ET

IntelGenx Reports Fourth Quarter and Full-Year 2022 Financial Results

IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and twelve-month periods ended December 31, 2022. All dollar amounts are expressed in U.S. currency, unless otherwise...

Mar 24, 2023 04:15 pm ET

IntelGenx Revises Fourth Quarter and Full Year 2022 Financial Results Reporting and Conference Call Date to March 29, 2023

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that, further to its press release of March 23, 2023, it now plans to release its fourth quarter and full year 2022 financial...

Mar 23, 2023 04:30 pm ET

IntelGenx to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023 – Conference Call to Follow

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its fourth quarter and full year 2022 financial results after market close on Thursday, March 30, 2023. An...

Mar 21, 2023 04:30 pm ET

IntelGenx Announces Closing of Notes Offering

IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) announces the closing of an offering by way of private placement (the “Offering”) to certain investors in the United States of convertible notes due March 1, 2027...

Mar 09, 2023 11:04 am ET

CORRECTION – IntelGenx to Participate in the 35th Annual Roth Conference

In a release issued under the same headline earlier today by IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT), please note that the time of the fireside chat has been updated. The corrected release follows: IntelGenx Technologies...

Mar 09, 2023 10:35 am ET

IntelGenx to Participate in the 35th Annual Roth Conference

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx”), a leader in pharmaceutical films, will be participating in the 35th Annual ROTH Conference, being held March 12–14, 2023 at the Ritz-Carlton Hotel in Dana Point,...

Feb 21, 2023 08:00 am ET

IntelGenx Receives USPTO Notice of Allowance for Loxapine Orange Book Eligible Patent

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx”), a leader in pharmaceutical films, today announced that the United States Patent and Trademark Office (“USPTO”) has granted a Notice of Allowance for U.S. Patent Application...

Feb 09, 2023 08:00 am ET

IntelGenx Announces Research Collaboration with Renowned Neurologist to Evaluate Montelukast VersaFilm® for the Treatment of Parkinson’s Disease

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx”), a leader in pharmaceutical films, today announced a research collaboration with Per Svenningsson, MD, PhD, of the Karolinska Institute, to plan and conduct a multicentre,...

Jan 23, 2023 08:00 am ET

IntelGenx and Arwan Enter into a Supply Agreement for RIZAPORT® in MENA Countries

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, announced today that it has entered into an exclusive supply agreement (the “Agreement”) for RIZAPORT® (the “Product”) with ARWAN...

Jan 09, 2023 08:00 am ET

IntelGenx Receives Fourth and Final Loan Tranche from atai

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company”) today announced that its wholly-owned subsidiary, IntelGenx Corp. (“IntelGenx”), has received a fourth and final term loan tranche (the “Loan”) in the amount of U.S.$3 million...

Dec 07, 2022 08:00 am ET

IntelGenx Announces Collaboration with UPEI to Evaluate Acceptance and Preference of VetaFilm™ Platform in Dogs and Cats

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx”), a leader in pharmaceutical films, today announced a research collaboration with the University of Prince Edward Island (“UPEI”) to assess palatability, owner-perceived...

Nov 22, 2022 07:30 am ET

IntelGenx Receives FDA PDUFA Date for RIZAFILM®

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that the U.S. Food and Drug Administration (”FDA”) has accepted for review its Class 2 response to the 2020 Complete Response...

Nov 10, 2022 05:54 pm ET

IntelGenx Reschedules Third Quarter 2022 Conference Call Due to Technical Issues Experienced Today by Webcast Vendor

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that its third quarter 2022 conference call, originally scheduled for today, will now be held tomorrow (Friday, November 11, 2022)...

Nov 10, 2022 04:05 pm ET

IntelGenx Reports Third Quarter 2022 Financial Results

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the third quarter ended September 30, 2022. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and...

Nov 09, 2022 07:30 am ET

IntelGenx Enters into Feasibility & Development Agreement For CBD-Infused VetaFilm™

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx”), a leader in pharmaceutical films, today announced that it has entered into a Feasibility Study & Development Agreement (the “Agreement”) with an undisclosed animal health...

Nov 03, 2022 04:30 pm ET

IntelGenx to Report Third Quarter 2022 Financial Results on November 10, 2022 – Conference Call to Follow

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its third quarter 2022 financial results after market close on Thursday, November 10, 2022. An...

Nov 02, 2022 08:00 am ET

IntelGenx Files Provisional U.S. Patent Application for Advanced Oral Film Formulation Improving Cannabinoid Onset of Action

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx”), a leader in pharmaceutical films, today announced it has filed a new provisional patent application with the United States Patent and Trademark Office (“USPTO”) entitled...

Oct 25, 2022 08:00 am ET

IntelGenx Receives FDA GDUFA Date for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that its previously undisclosed development candidate, Buprenorphine Buccal Film, for which an abbreviated new drug application (“ANDA”) has been filed by Chemo...

Oct 20, 2022 08:30 am ET

IntelGenx Announces Issuance of New U.S. Patent Covering VersaFilm® Technology

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,471,406 to IntelGenx, with claims for...

Oct 18, 2022 08:00 am ET

IntelGenx Submits Response to CRL from FDA for RIZAPORT® VersaFilm®

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that it has responded to the Complete Response Letter (“CRL”) for its 505(b)(2) New Drug Application (NDA) for RIZAPORT®...

Oct 13, 2022 09:21 am ET

IntelGenx’s Collaboration with atai Life Sciences Culminates in the Initiation of First-in-Human Clinical Study of an Oral Thin Film Psychedelic Drug Candidate

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today provided an update on its collaboration with its strategic partner, atai Life Sciences (NASDAQ:ATAI) (“atai”), for the development of novel formulations of...

Sep 08, 2022 08:00 am ET

IntelGenx Announces Enrollment Reaches Halfway Mark in ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that patient enrollment in the ongoing Montelukast VersaFilm® Phase 2a (“BUENA”) clinical trial in patients with mild to moderate Alzheimer’s Disease (“AD”) has...

Aug 11, 2022 04:05 pm ET

IntelGenx Reports Second Quarter 2022 Financial Results

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the second quarter ended June 30, 2022. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and...

Aug 04, 2022 08:30 am ET

IntelGenx to Report Second Quarter 2022 Financial Results on August 11, 2022 – Conference Call to Follow

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its second quarter 2022 financial results after market close on Thursday, August 11, 2022. An accompanying...

Jul 05, 2022 02:00 pm ET

IntelGenx Announces Completion of Share Issuance in Payment of Principal and Interest on Debentures

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) announces that, as previously disclosed on June 1, 2022 and in accordance with the terms of the trust indenture governing the Debentures (as defined below), as...

Jun 30, 2022 08:06 am ET

IIROC Trading Halt - IGX.DB

TORONTO, June 30, 2022 /CNW/ - The following issues have been halted by IIROC:

Jun 01, 2022 08:30 am ET

IntelGenx Announces Intention to Issue Shares in Payment of Principal and Interest on Outstanding Debentures

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) announces that it intends to (i) issue shares of common stock of the Company (“Shares”) in payment of the outstanding C$5,450,000 aggregate principal amount of the...

May 12, 2022 04:05 pm ET

IntelGenx Reports First Quarter 2022 Financial Results

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the first quarter ended March 31, 2022. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and...

May 10, 2022 04:05 pm ET

IntelGenx Announces Voting Results on Election of Directors and other items

IntelGenx Technologies Corp. (TSXV: IGX) (OTCQB: IGXT) (the “Company”) announces that shareholders voted in favour of all items of business put forth by the Company at the Annual Meeting of Shareholders held by virtual meeting on May 10, 2022...

May 05, 2022 04:30 pm ET

IntelGenx to Report First Quarter 2022 Financial Results on May 12, 2022 – Conference Call to Follow

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its first quarter 2022 financial results after market close on Thursday, May 12, 2022. An accompanying...

Apr 26, 2022 04:45 pm ET

IntelGenx to Participate in the 2022 Bloom Burton & Co. Healthcare Investor Conference

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that management will present an update on the Company’s business at the Bloom Burton & Co. Healthcare Investor Conference on...

Mar 24, 2022 04:03 pm ET

IntelGenx Reports Fourth Quarter and Full-Year 2021 Financial Results

IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and twelve-month periods ended December 31, 2021. All dollar amounts are expressed in U.S. currency, unless otherwise...

Mar 17, 2022 04:30 pm ET

IntelGenx to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022 – Conference Call to Follow

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its fourth quarter and full year 2021 financial results after market close on Thursday, March 24, 2022. An...

Feb 01, 2022 08:00 am ET

IntelGenx Receives Third Loan Tranche from atai

Further to its press release dated September 15, 2021, IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company”) today announced that its wholly-owned subsidiary, IntelGenx Corp. (“IntelGenx”) has received a third term loan (the “Third Loan”) in the...

Jan 20, 2022 08:00 am ET

First Patient Dosed in IntelGenx’s Resumed ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”), a leader in pharmaceutical films, today announced that patient dosing has resumed in the ongoing Phase 2a (“BUENA”) clinical trial in patients with mild to moderate Alzheimer’s...

Dec 08, 2021 08:00 am ET

IntelGenx Initiates Arbitration Proceeding Against Tilray® Related to an Alleged Breach of Worldwide Cannabis-Infused VersaFilm® Agreement

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has initiated an arbitration proceeding against Tilray, Inc. (“Tilray®”) related to an alleged breach of the parties’ 2018 license, development and supply...

Nov 11, 2021 04:03 pm ET

IntelGenx Reports Third Quarter 2021 Financial Results

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the third quarter ended September 30, 2021. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and...

Nov 04, 2021 04:30 pm ET

IntelGenx to Report Third Quarter 2021 Financial Results on November 11, 2021 – Conference Call to Follow

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its third quarter 2021 financial results after market close on Thursday, November 11, 2021. An accompanying...

Oct 12, 2021 11:00 am ET

IntelGenx Technologies Corp. Virtually Opens the Market

TORONTO, Oct. 12, 2021 /CNW/ - Horst Zerbe, Chief Executive Officer, IntelGenx Technologies Corp., (the "Company") (TSX: IGX) and his team joined Berk Sumen, Head of TSX Company Services, TMX Group, to celebrate the Company's graduation to Toronto Stock Exchange and open the market.

Oct 12, 2021 08:00 am ET

Patient Screening to Resume in IntelGenx’s ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”)), a leader in pharmaceutical films, today announced its intention to resume patient screening in the ongoing Montelukast VersaFilm® Phase 2a (“BUENA”) clinical trial in patients...

Oct 05, 2021 02:15 pm ET

IntelGenx Receives Final Approval to Graduate to Toronto Stock Exchange

IntelGenx Technologies Corp. (TSXV: IGX) (OTCQB: IGXT) (“IntelGenx” or ”the “Company”) announces that it has received final approval to graduate to the Toronto Stock Exchange (the “TSX”) from the TSX Venture Exchange (the “TSXV”). The Company’s...

Sep 29, 2021 04:30 pm ET

IntelGenx and Aquestive Therapeutics Partner with Leading Men’s Health Company to Market Tadalafil Oral Films in the U.S.

IntelGenx Corp. (TSXV:IGX) (OTCQB:IGXT) (“IntelGenx”) today announced that its co-development and commercialization partner for Tadalafil oral films for the treatment of erectile dysfunction (“ED”) and benign prostatic hyperplasia (BPH) (the...

Sep 15, 2021 08:00 am ET

IntelGenx Receives U.S.$6 Million in Additional Loans from atai Life Sciences and Conditional Approval to Graduate to Toronto Stock Exchange

IntelGenx Technologies Corp. (TSXV: IGX) (OTCQB: IGXT) (the “Company”) announces that its wholly-owned subsidiary, IntelGenx Corp. (“IntelGenx”), has entered into an amended and restated secured loan agreement (the “Loan Agreement”) with atai Life...

Sep 07, 2021 04:15 pm ET

IntelGenx Announces Market Launch of RIZAPORT® in Spain

IntelGenx Corp. (TSX V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Exeltis Healthcare S.L. (“Exeltis”), its commercialization partner in the European Union (“EU”) for RIZAPORT®, a unique for the treatment of acute...

Aug 31, 2021 08:00 am ET

IntelGenx Ships CBD Filmstrips to Heritage Cannabis in Support of Canadian Market Launch

IntelGenx Corp. (TSX-V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has completed an initial shipment of CBD Filmstrips in support of Heritage Cannabis Holdings Corp.’s (“Heritage Cannabis”) (CSE:CANN) Canadian market...

Aug 05, 2021 10:30 am ET

IntelGenx Announces Closing of Notes Offering

IntelGenx Technologies Corp. (TSXV: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) announces the closing of an offering by way of private placement (the “Offering”) to certain investors in the United States of 8% convertible notes due July 31,...

Aug 04, 2021 04:03 pm ET

IntelGenx Reports Second Quarter 2021 Financial Results

IntelGenx Technologies Corp. (TSX V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the second quarter ended June 30, 2021. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and...

Aug 04, 2021 09:00 am ET

IntelGenx Strengthens Board with the Appointments of Dr. Srinivas G. Rao and Frank Stegert

IntelGenx Technologies Corp. (TSX V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced the appointments of Srinivas (Srini) G. Rao, M.D., Ph.D. and Frank Stegert to its Board of Directors. The appointments of the two new directors were...

Jul 29, 2021 08:00 am ET

IntelGenX to Report Second Quarter 2021 Financial Results on August 4, 2021 – Conference Call to Follow

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”) today announced that it will release its second quarter 2021 financial results after market close on Wednesday, August 4, 2021. An accompanying conference call will be hosted by...

Jul 27, 2021 03:00 pm ET

IntelGenx Announces Subscription for Notes

IntelGenx Technologies Corp. (TSXV: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) announces that it has received subscriptions from investors in the United States for U.S.$2.1 million principal amount of 8% convertible notes due July 31, 2025...

Jun 08, 2021 08:00 am ET

IntelGenx’s VetaFilm™ Platform to be Evaluated by One of the World’s Fastest Growing Animal Healthcare Companies

IntelGenx Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it has entered into a Materials Transfer Agreement (the “Agreement”) with an undisclosed global veterinary health company (the “Partner)....

May 19, 2021 08:00 am ET

IntelGenx Announces Noteholder Approval of Proposed Amendments to Convertible Notes

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Corporation”) today announced that the holders (“Noteholders”) of its 6.0% convertible unsecured promissory notes due June 1, 2021, originally issued by private placement on...

May 14, 2021 01:30 pm ET

IntelGenx Announces Initial Closing of atai Investment

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today reported that the previously announced US$12,346,300 investment in IntelGenx by ATAI Life Sciences AG (“atai”) has been completed. As a...

May 13, 2021 04:05 pm ET

IntelGenx Reports First Quarter 2021 Financial Results

IntelGenx Technologies Corp. (TSX V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the first quarter ended March 31, 2021. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and...

May 12, 2021 08:30 am ET

IntelGenx Expands Psychedelics Collaboration with atai Life Sciences with Signing of Second Feasibility Agreement

IntelGenx Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it has entered into a second feasibility agreement (the “SFA”) with ATAI Life Sciences AG (“atai”), a clinical-stage biopharmaceutical...

May 11, 2021 03:34 pm ET

IntelGenx Announces Shareholder Approval of atai Investment

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that a significant majority of its shareholders have approved the resolution approving the previously announced investment in...

May 06, 2021 08:00 am ET

IntelGenx to Report First Quarter 2021 Financial Results on May 13, 2021 – Conference Call to Follow

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”) today announced that it will release its first quarter 2021 financial results after market close on Thursday, May 13, 2021. An accompanying conference call will be hosted by Dr....

Apr 09, 2021 08:00 am ET

IntelGenx Announces Intention to Amend Convertible Unsecured Promissory Notes

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it is proposing to amend the terms of its 6.0% convertible unsecured promissory notes due June 1, 2021, originally issued by...

Mar 31, 2021 06:00 pm ET

IntelGenx Ships First CBD Filmstrip Order to Heritage Cannabis

IntelGenx Corp. (TSX-V:IGX)(OTCQB:IGXT) ("Company" or "IntelGenx") today announced that, further to its press releases of January 7 and March 25, 2021, it has completed its first shipment, consisting of 75,000 CBD Filmstrips, to Heritage Cannabis...

Mar 25, 2021 04:05 pm ET

IntelGenx Reports Fourth Quarter and Full-Year 2020 Financial Results

IntelGenx Technologies Corp. (TSX V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx") today reported financial results for the fourth quarter and twelve-month periods ended December 31, 2020. All dollar amounts are expressed in U.S. currency, unless...

Mar 18, 2021 04:30 pm ET

IntelGenx to Report Fourth Quarter and Full-Year 2020 Financial Results on March 25, 2021 – Conference Call to Follow

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”) today announced that it will release its fourth quarter and full-year 2020 financial results after market close on Thursday, March 25, 2021. An accompanying conference call will...

Mar 15, 2021 08:00 am ET

IntelGenx Announces Strategic Partnership with atai Life Sciences and Proposed TSX Graduation

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (the “Corporation”) today announced that its wholly owned subsidiary, IntelGenx Corp. (“IntelGenx”), a leader in pharmaceutical films, has agreed to the terms of a strategic partnership with...

Feb 24, 2021 08:45 am ET

Kane Biotech Announces New Chairman

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), announced today current Board member Mark Nawacki will take over as Chairman of the Board, and Philip Renaud will assume the role of Vice Chair. “Over the past two...

Feb 17, 2021 08:00 am ET

IntelGenx Receives USPTO Notice of Allowance for its Novel DisinteQ™-Based Disintegrating THC Oral Film

IntelGenx Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”) today announced that the United States Patent and Trademark Office (“USPTO”) has granted a Notice of Allowance for US Patent Application 16/110,737, entitled “Film Dosage Form with Extended...

Feb 08, 2021 08:00 am ET

IntelGenx Files Provisional U.S. Patent Application for Novel VetaFilm™ High Loading Oral Film Platform

IntelGenx Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”) today announced that it has filed a new provisional patent application at the United States Patent and Trademark Office entitled “High Loading Oral Film Formulation.” The patent application...

Jan 12, 2021 04:15 pm ET

IntelGenx Appoints Tommy Kenny as Vice President, Intellectual Property and Legal Affairs, General Counsel

IntelGenx Technologies Corp. (TSXV: IGX) (OTCQB: IGXT) (“IntelGenx” or the “Company”) today announced that its Board of Directors appointed Mr. Tommy Kenny as Vice President, Intellectual Property and Legal Affairs, General Counsel of IntelGenx...

Jan 07, 2021 08:00 am ET

IntelGenx Receives First Purchase Order For CBD Filmstrips From Heritage Cannabis

IntelGenx Corp. (TSX-V:IGX)(OTCQB:IGXT) ("Company" or "IntelGenx") today announced the execution of a definitive supply agreement (the “Agreement”) with Heritage Cannabis Holdings (“Heritage”), an international medical cannabis licensed producer...

Jan 06, 2021 04:15 pm ET

IntelGenx Announces Issuance of Shares in Payment of Interest on Outstanding Debentures

IntelGenx Technologies Corp. (TSXV: IGX) (OTCQB: IGXT) (the “Corporation” or “IntelGenx”) announced that on December 31, 2020, it issued 887,880 common shares at a deemed price of C$0.335 per Common Share in payment of an aggregate of C$297,440 in...

Dec 08, 2020 08:15 am ET

IntelGenx Announces Issuance of Shares in Payment of Interest on Outstanding Debentures

IntelGenx Technologies Corp. (TSXV: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) announces that it intends to issue 899,940 common shares of the Corporation (the “Common Shares”) at a deemed price of CAD $0.335 per Common Share in payment of...

Nov 23, 2020 05:00 pm ET

IntelGenx Grants Stock Options

IntelGenx Technologies Corp. ("IntelGenx", or the “Company”) (TSX-V: IGX) (OTCQB:IGXT) announced today that the Company’s board of directors granted stock options to acquire a total of 1,365,000 common shares under the 2016 Stock Option Plan. Of...

Nov 12, 2020 04:05 pm ET

IntelGenx Reports Third Quarter 2020 Financial Results

IntelGenx Technologies Corp. (TSX V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the third quarter ended September 30, 2020. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and...

Nov 11, 2020 08:30 am ET

IntelGenx Announces Issuance of U.S. Patent for Novel Technology Applicable to Cannabis-Containing Oral Films

IntelGenx Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that the United States Patent and Trademark Office has issued U.S. Patent 10,828,254, entitled “Oral film formulation for modulating...

Nov 09, 2020 08:30 am ET

IntelGenx Announces Publication of a Study Evaluating Montelukast’s Effect on Neurological Aging

IntelGenx Corp. (TSX V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that the peer-reviewed journal, International Journal of Clinical Pharmacy, has published a study on Montelukast’s effect on neurological aging. “This study...

Nov 05, 2020 04:30 pm ET

IntelGenx to Report Third Quarter 2020 Financial Results on November 12, 2020 – Conference Call to Follow

IntelGenx Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”) today announced that it will release its third quarter 2020 financial results after market close on Thursday, November 12, 2020. An accompanying conference call will be hosted by Dr. Horst G....

Oct 29, 2020 08:00 am ET

IntelGenx Signs Letter of Intent with Heritage Cannabis for Long-Term Cannabis Filmstrip Supply Agreement

IntelGenx Corp. (TSX V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has executed a binding letter of intent (“LOI”) with Heritage Cannabis Holdings Corp. (“Heritage”), an international medical cannabis licensed producer...

Oct 23, 2020 07:15 pm ET

IntelGenx Announces Second Tranche Closing of Private Placement

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) is pleased to announce that it has closed a private placement (the “Offering”) to certain investors in the United States of U.S.$532,000 principal amount of 8%...

Oct 21, 2020 07:00 am ET

IntelGenx Enters Into Amended and Restated License Agreement with Tetra Bio-Pharma for Adversa® Mucoadhesive Delivery Technology for Dronabinol

IntelGenx Corp. (TSX-V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has entered into an amended and restated license agreement (the “Agreement”) granting Tetra Bio-Pharma (TSX:TBP)(OTCQB:TBPMF)(“Tetra”), a leader in...

Oct 15, 2020 07:38 pm ET

IntelGenx Closes U.S.$1.2 Million Private Placement Financing

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) announces the closing of an offering by way of private placement (the “Offering”) to certain investors in the United States of U.S.$1.2 million principal amount of...

Aug 27, 2020 08:00 am ET

IntelGenx and Exeltis Healthcare S.L. Expand RIZAPORT® Commercialization Agreement to Include the European Union

IntelGenx Corp. (TSX V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has granted Exeltis Healthcare, S.L. (“Exeltis”) an exclusive license to manufacture and commercialize RIZAPORT®, a unique oral thin film for the...

Aug 24, 2020 05:00 pm ET

IntelGenx Amends Stock Options

IntelGenx Technologies Corp. ("IntelGenx", or the “Company”) (TSX-V: IGX) (OTCQB:IGXT) announced today that the Company’s board of directors amended the expiration time of Stock Options granted to Andre Godin, President and CFO, under the 2006...

Aug 20, 2020 08:00 am ET

IntelGenx Enters into Feasibility Agreement with ATAI Life Sciences to Develop Pharmaceutical-Grade Polymeric Film-Based Psychedelics

IntelGenx Corp. (TSX V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has entered into a feasibility agreement (the “Agreement”) with ATAI Life Sciences AG (“ATAI”), a global biotech developing psychedelic and...

Aug 13, 2020 04:02 pm ET

IntelGenx Reports Second Quarter 2020 Financial Results

IntelGenx Technologies Corp. (TSX V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the second quarter ended June 30, 2020. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and...

Aug 06, 2020 05:16 pm ET

IntelGenx to Report Second Quarter 2020 Financial Results on August 13, 2020 – Conference Call to Follow

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its second quarter 2020 financial results after market close on August 13, 2020. An accompanying...

Jul 20, 2020 08:00 am ET

IntelGenx and Tilray® Agree to Amend Certain Exclusivity Terms of Worldwide Cannabis-Infused VersaFilm® Agreement

IntelGenx Corp. (TSX V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it and Tilray, Inc. (“Tilray®”) have amended the exclusivity terms of their November 2018 license, development and supply agreement (the “Agreement”) to...

Jul 15, 2020 05:44 pm ET

IntelGenx Reports Amendment of Stock Option Plan

IntelGenx Technologies Corp. (TSX-V: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) reported today, that the Company's Board of Directors approved an amendment to the Amended 2016 Stock Option Plan (the “Plan”) to increase the number of shares...

Jul 07, 2020 08:00 am ET

IntelGenx and Cybin Corp. Enter Into Feasibility Agreement for Fast-Acting, Orally-Dissolving Psilocybin Film

IntelGenx Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, is pleased to announce that it has entered into a feasibility agreement with Cybin Corp. (“Cybin”), Canada's premier mushroom life sciences company focused on...

Jun 25, 2020 09:47 am ET

IntelGenx Announces Approval of Proposed Amendments to Convertible Debentures

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Corporation”) today announced that the holders (“Debentureholders”) of its 8.0% convertible unsecured subordinated debentures due June 30, 2020, originally issued on July...

Jun 11, 2020 08:00 am ET

IntelGenx Provides Update on RIZAPORT® VersaFilm® NDA Resubmission Process Following Type A Meeting with the FDA

Saint Laurent, Quebec, June 11, 2020 – IntelGenx Corp. (TSX V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today provided an update regarding its RIZAPORT® VersaFilm® program following its Type A meeting with the U.S. Food & Drug Administration...

Jun 10, 2020 08:00 am ET

IntelGenx Poised to Launch Hand Sanitizer Business Following Receipt of Health Canada Authorization for Commercial Sale

IntelGenx Corp. (TSX V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Health Canada has authorized the sale of IntelGenx’s hand sanitizer product, both in liquid and gel formulations, which will be manufactured using excess...

Jun 08, 2020 08:00 am ET

IntelGenx Receives Health Canada Cannabis Micro-Processing License

IntelGenx Corp. (TSX V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that it has received a cannabis micro-processing license from Health Canada for the Company’s Montreal, Quebec facility, in...

May 28, 2020 08:00 am ET

IntelGenx Announces Intention to Issue Shares in Payment of Principal on Outstanding Debentures, and Meeting of Debentureholders

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Corporation”) today announced that it intends to issue shares of common stock (“Common Shares”) of the Corporation in payment of the outstanding $7,577,000 aggregate...

May 27, 2020 08:00 am ET

IntelGenx Confirms Type A Meeting with the FDA Regarding RIZAPORT® VersaFilm®

IntelGenx Corp. (TSX-V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that the U.S. Food & Drug Administration ("FDA") has granted the Company’s request for a Type A meeting related to its RIZAPORT® VersaFilm® program. This meeting...

May 14, 2020 04:02 pm ET

IntelGenx Reports First Quarter 2020 Financial Results

IntelGenx Technologies Corp. (TSX V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the first quarter ended March 31, 2020. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and...

May 12, 2020 08:00 am ET

IntelGenx Announces Intention to Amend Convertible Debentures

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it is proposing to amend the terms of its 8.0% convertible unsecured subordinated debentures due June 30, 2020, originally...

May 08, 2020 04:15 pm ET

IntelGenx to Report First Quarter 2020 Financial Results on May 14, 2020 – Conference Call to Follow

IntelGenx Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its first quarter 2020 financial results after market close on May 14, 2020. An accompanying conference call will be...

Apr 28, 2020 08:00 am ET

IntelGenx Provides Status Update on Cannabis Micro-Processing License Application

In response to investor and media inquiries, IntelGenx Technologies Corp. (TSX V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx") provided an update regarding its micro-processing license application for its Montreal, Quebec facility that is...

Apr 23, 2020 04:00 pm ET

IntelGenx Changes 2020 Annual Meeting of Stockholders to a Virtual-Only Format

IntelGenx Technologies Corp. (TSX V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that, due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic, and to...

Apr 06, 2020 08:00 am ET

IntelGenx Announces Adjusted VersaFilm® Business Strategy, Next Steps for RIZAPORT® VersaFilm® Program

IntelGenx Technologies Corp. (TSX V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced various initiatives aimed at helping the Company address, and satisfactorily respond to, the Complete Response...

Mar 27, 2020 11:52 am ET

IIROC Trading Resumption - IGX

VANCOUVER, March 27, 2020 /CNW/ - Trading resumes in:

Mar 27, 2020 11:46 am ET

IntelGenx Receives Complete Response Letter from FDA for RIZAPORT® NDA

IntelGenx Technologies Corp. (TSX V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that it has received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”)...

Mar 27, 2020 10:02 am ET

IIROC Trading Halt - IGX

VANCOUVER, March 27, 2020 /CNW/ - The following issues have been halted by IIROC:

Mar 26, 2020 07:00 am ET

IntelGenx Reports Fourth Quarter and Full-Year 2019 Financial Results

IntelGenx Technologies Corp. (TSX V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx") today reported financial results for the fourth quarter and twelve-month periods ended December 31, 2019. All dollar amounts are expressed in U.S. currency, unless...

Mar 23, 2020 08:00 am ET

INTELGENX TO REPORT FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS ON MARCH 26; CONFERENCE CALL TO FOLLOW ON MARCH 27

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its fourth quarter and full-year 2019 financial results before market open on Thursday, March 26, 2020. As previously...

Feb 11, 2020 10:14 am ET

IntelGenx Completes C$8.2 Million Equity Offering

IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) is pleased to announce that it has closed its offering (the “Offering”) of 16,317,000 units (the “Units”) at a price of C$0.50 per Unit (the “Offering Price”) for...

Jan 27, 2020 05:13 pm ET

IntelGenx Announces Pricing of Equity Offering

IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) announced today the pricing of an agency offering (the “Offering”) of up to 20,000,000 units, subject to a minimum offering of 10,000,000 units (the “Units”), for...

Jan 15, 2020 08:00 am ET

IntelGenx Receives Health Canada Authorization to Proceed with New Amendment for Montelukast VersaFilm® Phase 2a Trial

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that Health Canada has issued a No Objection Letter in response to IntelGenx’s amended Clinical Trial Application (“CTA”) for the ongoing...

Jan 13, 2020 08:00 am ET

IntelGenx Provides Commercial Update on its Two Lead VersaFilm® Product Candidates, Cannabis-Infused Oral Film and RIZAPORT®

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today provided a commercial update on its two lead product candidates, cannabis-infused VersaFilm® and RIZAPORT®. IntelGenx is providing this information...

Jan 09, 2020 08:00 am ET

IntelGenx Enters Animal Health Market by Signing Feasibility Agreement for VetaFilm™ Platform

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”) a leader in pharmaceutical films, today announced that it has entered into a Feasibility Study Agreement (the “Agreement”) with an undisclosed partner (the “Partner”) focused on bringing...

Dec 20, 2019 08:08 am ET

IIROC Trading Resumption - IGX

VANCOUVER, Dec. 20, 2019 /CNW/ - Trading resumes in:

Dec 19, 2019 04:30 pm ET

IntelGenx Files Preliminary Short Form Prospectus in Connection With a Proposed Offering of Units

IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) is pleased to announce that it has filed a preliminary short form prospectus (the “Prospectus”) with respect to an offering (the “Offering”) of units (“Units”)...

Dec 19, 2019 03:29 pm ET

IIROC Trading Halt - IGX

VANCOUVER, Dec. 19, 2019 /CNW/ - The following issues have been halted by IIROC:

Dec 06, 2019 08:00 am ET

IntelGenx Announces Issuance of Shares in Payment of Interest on Outstanding Debentures

IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) announces that it intends to issue 415,178 common shares of the Corporation (the “Common Shares”) at a deemed price of CAD $0.73 per Common Share in payment of an...

Dec 03, 2019 08:00 am ET

IntelGenx to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference

IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that management will present an update on the Company’s business at the first annual BioTuesdays Pre-JPM Virtual...

Nov 07, 2019 04:01 pm ET

IntelGenx Reports Third Quarter 2019 Financial Results

IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today reported financial results for the third quarter ended September 30, 2019. All dollar amounts are expressed in U.S....

Nov 01, 2019 01:18 pm ET

IntelGenx to Report Third Quarter 2019 Financial Results on November 7, 2019 – Conference Call to Follow

IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that it will release its third quarter 2019 financial results after market close on November 7, 2019. An...

Oct 31, 2019 05:07 pm ET

IntelGenx Initiates Scale-Up Work for Cannabis-Infused Oral Film Product

IntelGenx Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that it has progressed to the manufacturing scale-up stage in its cannabis-infused VersaFilm® product co-development program....

Oct 22, 2019 08:00 am ET

IntelGenx Announces FDA’s Acceptance of Resubmitted RIZAPORT® New Drug Application

IntelGenx Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that its 505(b)(2) New Drug Application (“NDA”) for RIZAPORT® VersaFilm® for the treatment of acute migraines has been...

Oct 09, 2019 08:00 am ET

IntelGenx Receives Positive DSMB Recommendation for Montelukast VersaFilm® Phase 2a Trial

IntelGenx Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that an independent Data Safety Monitoring Board (“DSMB”) completed its first interim analysis of the ongoing Montelukast...

Sep 26, 2019 04:34 pm ET

IntelGenx Announces Resubmission of RIZAPORT® New Drug Application

IntelGenx Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that it has resubmitted its 505(b)(2) New Drug Application (“NDA”) for RIZAPORT® VersaFilm® for the treatment of acute...

Sep 03, 2019 04:30 pm ET

IntelGenx to Present at the H.C. Wainwright 21st Annual Global Investment Conference

IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that its CEO, Dr. Horst G. Zerbe, is scheduled to present at the H.C. Wainwright 21st Annual Global Investment...

Aug 08, 2019 04:00 pm ET

IntelGenx Reports Second Quarter 2019 Financial Results

IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today reported financial results for the second quarter ended June 30, 2019. All dollar amounts are expressed in U.S. currency...

Aug 01, 2019 04:30 pm ET

IntelGenx to Report Second Quarter 2019 Financial Results on August 8, 2019 – Conference Call to Follow

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its second quarter 2019 financial results after market close on August 8, 2019. An accompanying conference call will be...

Jul 10, 2019 08:00 am ET

IntelGenx to Present at 12th Edition of Clinical Trials on Alzheimer’s Disease

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will present a Montelukast poster at the 12th edition of Clinical Trials on Alzheimer’s Disease (CTAD2019), to be held in San Diego,...

Jun 19, 2019 08:00 am ET

IntelGenx Announces Addition of Peterborough’s Kawartha Centre as Montelukast VersaFilm® Phase 2a Clinical Trial Site

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that, the Kawartha Centre has agreed to participate in IntelGenx’s Montelukast VersaFilm® Phase 2a BUENA clinical trial in patients with mild...

Jun 10, 2019 08:00 am ET

IntelGenx Announces Addition of Ottawa Montelukast VersaFilm® Phase 2a Clinical Trial Site; First Patient in Study Completes 26-Week Treatment

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), leader in pharmaceutical films, today announced that it has added a new Ottawa site in the Montelukast VersaFilm® Phase 2a (“BUENA”) clinical trial in patients with mild to moderate...

May 28, 2019 08:00 am ET

IntelGenx Receives First Shipment of Cannabis Extract from Tilray® for Production of Cannabis-Infused Oral Film

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today provided an update on its cannabis-infused VersaFilm® product co-development program with Tilray, Inc. (NASDAQ:TLRY) (“Tilray®”), a global leader in...

May 23, 2019 08:00 am ET

IntelGenx to Join the Quebec Pavilion at BIO 2019 International Convention

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), leader in pharmaceutical films, today announced that it will be joining the Quebec Pavilion at Booth #2627 at BIO 2019 International Convention taking place on June 3-6, 2019 in Philadelphia,...

May 09, 2019 04:00 pm ET

IntelGenx Reports First Quarter 2019 Financial Results

IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx") today reported financial results for the first quarter ended March 31, 2019. All dollar amounts are expressed in U.S. currency and results are reported in...

May 08, 2019 04:15 pm ET

IntelGenx Announces the Appointment of André Godin as President and Chief Financial Officer

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that its Board of Directors appointed André Godin to the position of President in addition to his current position as the...

May 08, 2019 07:00 am ET

IntelGenx and Aquestive Therapeutics Enter Worldwide Collaboration Agreement for Tadalafil

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that it has entered into a definitive worldwide agreement with Aquestive Therapeutics, Inc. (NASDAQ:AQST) (“Aquestive”), a specialty...

May 02, 2019 08:00 am ET

IntelGenx to Report First Quarter 2019 Financial Results on May 9, 2019 – Conference Call to Follow

IntelGenx Technologies Corp. (TSX VENTURE:IGX) (OTCQX:IGXT) today announced that it will release its first quarter 2019 financial results after market close on May 9, 2019. An accompanying conference call will be hosted by Dr. Horst G. Zerbe,...

May 01, 2019 08:00 am ET

IntelGenx Announces Issuance of Second U.S. Patent for Topical Oral Film Technology

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that the United States Patent and Trademark Office has issued U.S. Patent 10,272,038 entitled “Film Dosage Form with Extended Release...

Apr 25, 2019 08:00 am ET

IntelGenx to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that its Executive Vice-President and Chief Financial Officer, Andre Godin, is scheduled to present at the 2019 Bloom Burton & Co....

Apr 23, 2019 08:00 am ET

IntelGenx to Promote Oral Films CDMO Services at CPhI North America

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that it will promote its contract development and manufacturing organization (“CDMO”) services capabilities using its existing proprietary...

Apr 16, 2019 08:00 am ET

IntelGenx Files Non-Provisional U.S. Patent Application for Oil-Based Active Ingredients

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that it has filed a new non-provisional patent application at the Unites States Patent and Trademark Office entitled “Lipophilic Active...

Apr 08, 2019 08:00 am ET

IntelGenx to Promote VetaFilm™ Oral Film Technology at Human Biotech & Animal Health Business Partnering Summit

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that it will promote its proprietary VetaFilm™ oral film technology for companion animal drug delivery at the Human Biotech & Animal...

Apr 04, 2019 08:00 am ET

IntelGenx Presents at 14th International Conference on Alzheimer’s and Parkinson’s Disease

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced its two Montelukast poster presentations received positive and constructive feedback from the Alzheimer’s Disease (AD) scientific...

Apr 02, 2019 08:00 am ET

IntelGenx Receives Complete Response Letter from FDA for RIZAPORT® NDA

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced it has received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its resubmitted 505(b)(2)...

Mar 27, 2019 05:01 pm ET

IntelGenx Grants Stock Options

IntelGenx Technologies Corp. ("IntelGenx", or the “Company”) (TSX-V: IGX) (OTC.QX:IGXT) announced today that the Company’s board of directors granted 100,000 options to acquire 100,000 common shares under the 2016 Stock Option Plan to Rodolphe...

Mar 22, 2019 04:05 pm ET

IntelGenx Reports Fourth Quarter and Full-Year 2018 Financial Results

IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx") today reported financial results for the fourth quarter and twelve-month periods ended December 31, 2018. All dollar amounts are expressed in U.S. currency and...

Mar 18, 2019 04:00 pm ET

IntelGenx to Report Fourth Quarter and Full-Year 2018 Financial Results on March 25, 2019 – Conference Call to Follow

IntelGenx Technologies Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) today announced that it will release its fourth quarter and full year 2018 financial results after market close on March 25, 2019. An accompanying conference call will be hosted by...

Feb 14, 2019 08:00 am ET

IntelGenx Announces Montreal’s Douglas Mental Health University Institute as Ninth Montelukast VersaFilm™ Phase 2a Clinical Trial Site

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that, subject to final research ethics board approval, Montreal’s Douglas Mental Health University Institute has agreed to participate in...

Feb 11, 2019 08:00 am ET

IntelGenx Granted Japanese Patent for RIZAPORT® VersaFilm™

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that it has received a Decision to Grant notice from the Japanese Patent Office (JPO) to issue a patent entitled “Instantly wettable oral...

Feb 07, 2019 04:00 pm ET

IntelGenx Strengthens Senior Management Team

IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT), today announced that it has strengthened its management team with the appointment of Dr. Rodolphe Obeid to the position of Vice President, Operations of IntelGenx Corp. Dr. Obeid is an...

Jan 30, 2019 08:00 am ET

IntelGenx Facility Undergoes U.S. FDA Pre-Approval Inspection Related to RIZAPORT® NDA

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that the U.S. Food and Drug Administration (“FDA”) has performed a Pre-Approval Inspection (“PAI”) of the company’s Health...

Jan 23, 2019 08:00 am ET

IntelGenx Provides Update on Phase 2a Montelukast VersaFilm™ Clinical Trial

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today provided an update on its Phase 2a study of Montelukast VersaFilm™ in patients with mild to moderate Alzheimer’s Disease (AD). To date, seven study...

Jan 14, 2019 08:00 am ET

IntelGenx Provides Update on Cannabis-Infused VersaFilm™ Program Following Recently Proposed Amendments to the Cannabis Act

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today provided an update on its cannabis-infused VersaFilmTM product co-development program with Tilray, Inc. (NASDAQ:TLRY) (“Tilray®”) following the...

Dec 26, 2018 04:00 pm ET

IntelGenx Grants Restricted Share Units

IntelGenx Technologies Corp. ("IntelGenx", or the “Company”) (TSX-V: IGX) (OTC.QX:IGXT) announced today that the Company’s board of directors granted Restricted Share Units (RSU’s) to acquire a total of 53,846 common shares under the Company’s PRSU...

Dec 12, 2018 08:00 am ET

IntelGenx Partners with Gensco® Pharma to Market RIZAPORT® in the United States

IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced the execution of a definitive licensing, development and supply agreement (the “Agreement”) with Gensco® Pharma (Gensco®), a specialty...

Dec 05, 2018 04:54 pm ET

IntelGenx Reports Amendment of Stock Option Plan

IntelGenx Technologies Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) reported today, that the Company's Board of Directors approved to amend the 2016 Stock Option Plan (the “Plan”) to increase the number of shares available for...

Nov 30, 2018 08:00 am ET

IntelGenx Engages Focus Communications for Investor Relations Program

IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) is pleased to announce the engagement of Focus Communications (“Focus”) to provide online marketing and corporate communications services to the Company. Focus has been...

Nov 27, 2018 08:00 am ET

IntelGenx Begins Montelukast VersaFilm™ Dosing in Patients with Mild to Moderate Alzheimer’s Disease in Phase 2a Study

IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today announced that patient dosing has commenced in the Phase 2a study of Montelukast VersaFilm™ in patients with mild to moderate Alzheimer’s Disease (AD). The True North...

Nov 20, 2018 08:00 am ET

IntelGenx Announces FDA’s Acceptance of Resubmission of New Drug Application for RIZAPORT®

IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today announced that its 505(b)(2) New Drug Application (“NDA”) resubmission for RIZAPORT® oral soluble film 10 mg for the treatment of acute migraines has been accepted for...

Nov 13, 2018 04:00 pm ET

IntelGenx Closes Private Placement Financing

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) (the “Company” or “IntelGenx”) announces the closing of Tilray, Inc.’s strategic investment in IntelGenx by way of private placement (the “Private Placement”). Pursuant to the Private Placement,...

Nov 08, 2018 04:00 pm ET

IntelGenx Reports Third Quarter 2018 Financial Results

IntelGenx Technologies Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today reported financial results for the third quarter ended September 30, 2018. All dollar amounts are expressed in U.S. currency and results are reported in...

Nov 07, 2018 08:00 am ET

IntelGenx Announces Definitive Agreement with Tilray® to Form an Exclusive, Worldwide Partnership for Cannabis-Infused VersaFilm™ Products

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced the execution of a definitive license, development and supply agreement (the “Agreement”) with Tilray, Inc. (NASDAQ:TLRY) (“Tilray®”), a...

Nov 01, 2018 04:00 pm ET

IntelGenx to Report Third Quarter 2018 Financial Results on November 8, 2018 – Conference Call to Follow

IntelGenx Technologies Corp. (TSX VENTURE:IGX) (OTCQX:IGXT) today announced that it will release its third quarter 2018 financial results after market close on November 8, 2018. An accompanying conference call will be hosted by Dr. Horst G. Zerbe,...

Oct 31, 2018 08:00 am ET

The Spanish Agency of Medicines and Medical Devices Grants Marketing Authorization of RIZAPORT®

IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) is pleased to announced that its commercialization partner for RIZAPORT® (10mg) in Spain, Groupo Juste, which is now part of Exceltis Healthcare, has received national...

Oct 26, 2018 04:02 pm ET

IntelGenx Announces Exercise of Over-Allotment Option

IntelGenx Technologies Corp. (TSXV:IGX) (OTCQX:IGXT) (the “Company” or “IntelGenx”) announces that in connection with its previously announced public offering (the “Offering”) of units of the Company (the “Units”) for aggregate gross proceeds of...

Oct 22, 2018 06:53 pm ET

IntelGenx Completes US$12 Million Equity Offering

IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) is pleased to announce that it has closed its offering (the “Offering”) of 17,144,314 units (the “Units”) at a price of US$0.70 (the “Offering Price”) for gross...

Oct 18, 2018 10:07 am ET

IIROC Trading Resumption - IGX; IGX.DB

VANCOUVER, Oct. 18, 2018 /CNW/ - Trading resumes in:

Oct 18, 2018 09:51 am ET

IntelGenx Announces Pricing of $12 Million Equity Offering

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) (the “Company” or “IntelGenx”) announced today the pricing of an agency offering (the “Offering”) of 17,144,314 units (the “Units”) for gross proceeds of approximately US$12,000,000 million at a...

Oct 17, 2018 04:28 pm ET

IIROC Trading Halt - IGX, IGX.DB

VANCOUVER, Oct. 17, 2018 /CNW/ - The following issues have been halted by IIROC:

Oct 17, 2018 04:25 pm ET

IntelGenx Announces Proposed Equity Offering

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) (the “Company” or “IntelGenx”) today announced that it intends to distribute units (the “Units”), each Unit consisting of one share of common stock and one half of one warrant, each whole...

Oct 17, 2018 08:00 am ET

IntelGenx Receives Over $1.6 Million from Exercise of Warrants

IntelGenx Technologies Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) is pleased to announce that, since September 15, 2018, it has received proceeds of US$1,634,294 as a result of the exercise of 2,894,606 previously issued common...

Ad blocking detected

IntelGenx Technologies Corp. (T:IGX)

Business Focus: Generic Pharmaceuticals